The Bill & Melinda Gates Foundation, Novo Nordisk Foundation, and Wellcome are collaborating on a $50 million effort to boost ...

Infections by multidrug resistant organisms (MDROs) are a global health threat with a worrying increasing trend. In fragile ...

A Cornell University-led collaboration has uncovered the equipment that enables bacteria to survive exposure to antibiotics: ...

AbbVie has claimed FDA approval for Emblaveo, a new antibiotic product to treat complicated intra-abdominal infections (cIAI) ...

Research into developing new antimicrobial resistance treatment in Nigeria and other low/middle-income countries has fuelled a ...

Aztreonam–avibactam is a promising treatment for complicated intra-abdominal infections and hospital-acquired or ...

Research into developing new antimicrobial resistance treatments in Nigeria and other low/middle-income countries has secured ...

AbbVie has announced that the US Food and Drug Administration (FDA) has approved its Pfizer-partnered Emblaveo ...

LpxC inhibitors are emerging as a promising class of antibiotics targeting Gram-negative bacteria, which are notorious for their resistance to many existing antibiotics. LpxC, an essential enzyme ...

A study reveals alarming rates of antibiotic resistance in Gram-negative bacteria, highlighting the urgent need for ...

Antimicrobial resistance (AMR) is a major 21st century global health challenge. Multidrug-resistant Gram-negative bacteria (MDR-GNB) contribute a significant portion of the AMR threat, with an ...